Bolivia apuesta por desarrollar un suero hiperinmune contra la COVID-19 con base en el plasma de burros que ayudaría a “neutralizar el virus” en casos moderados y severos de esta enfermedad, que es más potente que el plasma donado por humanos. (Fuente: EFE)
:quality(75)/cdn.jwplayer.com/v2/media/VBFEpuMq/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/liBsLufe/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FACEUXZLE5DNHFQEAYVP66PHSI.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ZJRMYQTLGVFTTCQZDWD6JUNJ34.png)
:quality(75)/cdn.jwplayer.com/v2/media/JMggmIoe/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/lupTafqG/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/2pfQ89VL/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/xzRAq8rj/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FACEUXZLE5DNHFQEAYVP66PHSI.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ZJRMYQTLGVFTTCQZDWD6JUNJ34.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/HQ6UNSPCJFBRZG6O34HWHMLUTM.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/U47F2OCVQ5ENZNUWNUBDZSM25Q.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/VBFEpuMq/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/BIFQ4DBPG5HK3BPPVCJFY52GXQ.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/EFe5YLBq/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/YUSSR3R3VFAE3MVB55WBZUCA3A.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/V2ABWUUBNNAEZJ4FSI64SU5O3U.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/TVKBQS3TEJATNJ2O5DPSM6WRRQ.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X2QRKIHNP5FBPGUBVJF6UKVRTE.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/LN5NFMU725AWJMDEOWJWA5AA7U.png)
:quality(75)/cdn.jwplayer.com/v2/media/koNs9MA2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6bLTGi5d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/KgeU8b6Q/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a6mwPQ4X/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/nu9nKgwG/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/GCHGHNUMHVAIDBFA2VHOVRIAMY.png)
:quality(75)/cdn.jwplayer.com/v2/media/ttfzLB8n/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/c0S03whF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/azLadx4o/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FQ5XSTUGQ5DI3DYDC3MUSLQL6A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9a1H4G0a/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/EXTCEP2GUBC7XBDWQE34RG4BO4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/DOIUFLVUQ5AJDN2ZVTQQC7KHZ4.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/dXst1BW1/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/OVGLA7HDHJDQ7J5ABEIWMUQZBE.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/JW2JBE7IBZEY5NR2VH4KVTPGZ4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/42WZKDIDGVA6VKQDF75376W2CA.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ENCJ6JEIFZHT5E6UXK3KZ5RCUU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ27WLDNBFBCPCMLG42DQCNJYA.png)